The Fred Report - Weekly July 11, 2022

View a Printer Friendly version of this page, allowing you to print the page.

Market internals did NOT improve as much as we thought they should, which suggests that this is not a final bottom.  It is worth noting that some very long-term measures of breadth have become very oversold. This confirms our view that a dollar cost averaging methodology is correct.  Biotech could be strong speculative ideas for the second half of 2022.



Sorry this page is available to subscribers only.
If you're not a subscriber why not join today?

If you are already a subscriber, please login.

If you believe you should be able to view this area, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

 

 

 

Who is Fred Meissner, CMT?
Listen here:

The FRED Report is not authorized, endorsed, or affiliated with the Federal Reserve of St Louis and its FRED Economic Data.